Three 'Goode' stocks for Christmas
Three 'Goode' stocks for Christmas
About this video
Key Points:
Cyclopharm (ASX:CYC) could see major US growth following FDA approval and new key agreements
Imdex (ASX:IMD) offers strong upside tied to gold price recovery and rising exploration activity
Wagners (ASX:WGN) benefits from composite fibre technology demand and Queensland infrastructure projects
All three stocks are viewed as attractively valued for the upcoming period
Lucas Goode from Investors Mutual highlights three ASX-listed stocks he views as standouts heading into the Christmas period, focusing on Cyclopharm (ASX:CYC), Imdex (ASX:IMD), and Wagners (ASX:WGN). Goode points out that Cyclopharm, a provider of lung imaging gases for diagnosing pulmonary embolism, has struggled with its share price due to slower-than-expected US rollout. However, he states that the company now boasts FDA approval, a profitable business outside the US, and significant new agreements, including with Veterans Affairs and UnitedHealthCare. Goode suggests the market may have underestimated its US market potential, given 90% international market share and a $180 million addressable market in the US.
Goode also discusses Imdex, asserting it stands apart from traditional mining services as a technology leader in exploration. He notes half of Imdex's business is tied to gold, with performance closely linked to the gold price. Recent strong activity in junior explorers and historic precedents suggest robust potential revenue growth if exploration continues to rebound.
On Wagners, Goode highlights its strong position in Queensland’s construction market, with recent upgrades driven by its composite fibre technology unit, which produces long-lasting utility poles. With the Queensland infrastructure boom and additional exposure to east coast projects, Goode maintains Wagners offers compelling value.